伦伐替尼治疗晚期肝细胞癌相关副作用及症状群管理的临床意义

安林静; 张昕; 杨滢; 沙花燕; 黄顺; 王亚东

doi:10.3969/j.issn.1001-5256.2019.07.017

伦伐替尼治疗晚期肝细胞癌相关副作用及症状群管理的临床意义

DOI: 10.3969/j.issn.1001-5256.2019.07.017

解放军总医院第五医学中心护理部

基金项目:

国家重大专项基金资助项目(2008ZX10002-018)；首都临床特色重点基金资助项目(Z151100004015221)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2181
- HTML全文浏览量: 57
- PDF下载量: 320
- 被引次数: 0
出版历程
- 收稿日期: 2019-04-12
- 出版日期: 2019-07-20

Clinical significance of the management of adverse events and symptom cluster associated with advanced hepatocellular carcinoma after lenvatinib treatment

Nursing Department, The Fifth Medical Center of Chinese PLA General Hospital

Research funding:

摘要

摘要: 目的观察晚期肝细胞癌（HCC）患者接受分子靶向药物伦伐替尼治疗后出现的相关症状及症状群,探讨症状、症状群管理对减少3级以上相关不良事件和不良事件导致停止治疗的临床意义。方法纳入2017年5月-2018年12月在解放军总医院第五医学中心接受伦伐替尼治疗的晚期HCC患者98例。依据美国国立癌症研究所药物相关毒性判定标准,观察伦伐替尼相关副作用;以症状或症状群管理减少相关不良事件导致伦伐替尼剂量减少或中断或终止治疗例数为主要终点。结果 98例患者完成了全部观察,伦伐替尼相关副作用发生率> 20%,依次为高血压（42. 9%）、腹泻（33. 7%）、肝性脑病（30. 6%）、食欲减退（30. 6%）、蛋白尿（25. 5%）、疲乏（25. 5%）、手足综合征（22. 4%）、声音嘶哑（20. 4%）、体质量下降（20. 4%）; 3或4级不良反应发生54例（55. 1%）,常见3级副作用是高血压（8. 2%）,次之肝性脑病（6. 1%）; 4级不良反应发生1例（1%）。常见症状群依次为高血压蛋白尿症状群（56. 1%）、消化道综合征（50%）和疼痛综合征（36. 7%）。经过症状或症状群管...
- 癌,肝细胞 /
- 伦伐替尼 /
- 药物相关性副作用和不良反应
Abstract: Objective To investigate the symptoms and symptom clusters in patients with advanced hepatocellular carcinoma ( HCC) receiving molecular-targeted therapy with lenvatinib, as well as the clinical significance of the management of symptoms and symptom clusters in reducing lenvatinib-related grade 3 or above adverse events ( AEs) and AEs leading to treatment termination. Methods A total of 98 patients with advanced HCC who were treated with lenvatinib in The Fifth Medical Center of Chinese PLA General Hospital from May 2017 to December 2018 were enrolled. The AEs associated with lenvatinib were observed according to National Cancer Institute Common Toxicity Criteria, and the primary endpoint was the number of cases with a reduced dose or interruption of lenvatinib or treatment termination due to lenvatinib-related AEs after the management of symptoms or symptom clusters. Results All 98 patients completed the whole procedure.As for the lenvatinib-related AEs with an incidence rate of > 20%, hypertension had the highest incidence rate of 42. 9%, followed by diarrhea ( 33. 6%) , hepatic encephalopathy ( 30. 6%) , anorexia ( 30. 6%) , proteinuria ( 25. 5%) , fatigue ( 25. 5%) , hand-foot syndrome ( 22. 4%) , hoarseness ( 20. 4%) , and weight loss ( 20. 4%) . The incidence rate of grade 3 or 4 AEs was 55. 1% ( 54/98) ; the most common grade 3 AEs were hypertension ( 8. 2%) and hepatic encephalopathy ( 6. 1%) , and grade 4 AE was observed in 1 patient ( 1%) . The most common symptom clusters included hypertensive proteinuria ( 56. 1%) , digestive tract syndrome ( 50%) , and pain syndrome ( 36. 7%) . Among the 98 patients, 41 ( 41. 8%) had a reduced dose or interruption of lenvatinib due to lenvatinib-related AEs after the management of symptoms and symptom clusters and 4 ( 4. 1%) experienced treatment termination, which was lower than the percentages of 52. 9% and 8. 8% in the REFLECT study. Conclusion Hypertension and diarrhea are common AEs associated with lenvatinib. Hypertensive proteinuria, digestive tract syndrome, and pain syndrome are the main symptom clusters. Symptom cluster management is an effective means to reduce lenvatinib-related AEs leading to treatment termination.
- carcinoma, hepatocellular /
- lenvatinib /
- drug-related side effects and adverse reactions

HTML全文

参考文献(13)

[1]FREDDIE B, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018[J].Ca Cancer J Clin, 2018, 68 (6) :394-424.

[2]CHEN W, ZHENG R, BAADE PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66, 2:115-132.

[3]LI XC, WANG K, LI CX, et al.Clinical efficacy and prognostic factors analysis of radical hepatectomy of hepatocellular carcinoma in 760 patients[J].Chin J Dig Surg, 2017, 16 (4) :398-404. (in Chinese) 李相成, 王科, 李长贤, 等.760例肝细胞癌根治术的临床疗效及预后因素分析[J].中华消化外科杂志, 2017, 16 (4) :398-404.

[4]KUDO M, FINN RS, QIN S, et al.A Randomised Phase 3 trial of lenvatinib vs.sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma[J].Lancet, 2018, 391 (10126) :1163-1173.

[5]KUDO M.Lenvatinib may drastically change the treatment landscape of heparocellular carcinoma[J].Liver Cancer, 2018, 7 (1) :1-19.

[6]AN LJ, ZHANG X, ZHANG LN, et al.Randomized controlled trial of nurse intervention of urea-based cream on sorafenib-associated hand-foot skin reactions of patients[J].J Clin Med Pract, 2014, 18 (22) :45-47. (in Chinese) 安林静, 张昕, 张丽娜, 等.尿素乳膏护理干预索拉非尼相关手足皮肤反应随机对照研究[J].实用临床医药杂志, 2014, 18 (22) :45-47.

[7]AKTAS A, WALSH D, RYBICKI L.Symptom clusters and prognosis in advanced cancer[J].Support Care Cancer, 2012, 20 (11) :2837-2843.

[8]CAO W, LI J, HU C, et al.Symptom clusters and symptom interference of HCC patients undergoing TACE:A cross-sectional study in China[J].Support Care Cancer, 2013, 21 (2) :475-483.

[9] National Health and Family Planning Commission of the People’s Republic of China.Diagnosis, management, and treatment of hepatocellur carcinoma (V2017) [J].J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊治规范化 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.

[10]GE NL, XUE TC, YE SL.Interpretation of EASL Clinical Practice Guidelines:Management of hepatocellular carcinoma (2018) [J].J Clin Hepatol, 2018, 34 (6) :1187-1190. (in Chinese) 葛宁灵, 薛同春, 叶胜龙.《2018年欧洲肝病学会临床实践指南:肝细胞癌的管理》解读[J].临床肝胆病杂志, 2018, 34 (6) :1187-1190.

[11]National Cancer Institute. (2013) .Common Terminology Criteria for Adverse Events (CTCAE) v4.0.2011[EB/OL].[2013-09-11].http://ctep.cancer.gov/protocol Development/electronic_applications/ctc.htm.

[12]Chinese Society of Hepatology, Chinese Medical Association.Guidelines on the management of hepatic encephalopathy in cirrhosis[J].J Clin Hepatol, 2018, 34 (10) :2076-2089. (in Chinese) 中华医学会肝病学分会.肝硬化肝性脑病诊疗指南[J].临床肝胆病杂志, 2018, 34 (10) :2076-2089.

[13]IKEDA K, KUDO M, KAWAZOE S, et al.Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma[J].J Gastroenterol, 2017, 52 (4) :512-519.

施引文献

资源附件(0)

访问统计